

Advances in Uterine Leiomyoma Research: 2nd NIH International Congress



Office of Research on Women's Health
National Institutes of Health

U.S. Department of Health and Human Services

February 24-25, 2005
National Institutes of Health
William H. Natcher Conference Center, Building 45
Bethesda, MD

Advances in Uterine Leiomyoma Research
2nd NIH International Congress:
National Institute of Environmental Health Sciences
Attn: Dr. Barbara Davis
MD B3-06
P.O. Box 12233
RTP, NC 27709

Organizing Committee

Congress Co-Chairs

Dr. Vivian W. Pinn ORWH, NIH
Dr. Barbara J. Davis NIEHS, NIH

Program Co-Chairs

Dr. J. Carl Barrett NCI, NIH
Dr. Estella Parrott NICHD, NIH
Dr. James Segars NICHD, NIH

Abstracts Chairs

Dr. Susan Meikle, Chair AHRQ
Dr. Shelia McClure, Co-Chair NCRR, NIH

Steering Committee

Ms. Duiona R. Baker	Ms. Lisa Kaeser
Dr. Lisa Begg	Ms. Mary Lawrence
Dr. Rosaly Correa-de-Araujo	Dr. Phyllis Leppert
Dr. Loretta Finnegan	Ms. Sabrina Matoff
Ms. Mary Gant	Dr. Lynnette Nieman
Ms. Yvonne Green	Mr. Colin Pollard
Dr. Joan Harmon	Dr. Ahalya Premkumar
Dr. Wanda K. Jones	Ms. Joyce Rudick
Dr. Joseph Kaczmarczyk	Dr. Maura Whiteman
	Dr. Susan Wood

Conference Objectives

Uterine leiomyoma (fibroids) are the most common gynecologic neoplasm in women of reproductive age. As the number one cause of hysterectomy, they have a profound negative impact on women's health. Uterine leiomyoma are hormonally dependent and as such are a potential target for endocrine active compounds in the environment.

The goal of this conference is to bring together researchers working in the fields of biomedicine, epidemiology, basic research, therapeutics, and translational medicine to foster an exchange of scientific information among members of the uterine leiomyoma research and health care communities. Participants will be drawn from academia, medical centers, government and industry.

Topics to be covered include Clinical Experience and Therapeutic Strategies, Epidemiology, Clinical Trials, Pathogenesis of Smooth Muscle Tumors, and Molecular and Genetic Characteristics.

Sponsors

National Institutes Of Health

Office Of Research On Women's Health
National Institute Of Environmental Health Sciences
National Institute Of Child Health And Human Development
National Cancer Institute
National Institute Of Biomedical Imaging And Bioengineering
National Center For Research Resources
Agency For Healthcare Research And Quality
Centers For Disease Control And Prevention
Food And Drug Administration
Office on Women's Health, Office of the Secretary
Substance Abuse and Mental Health Services Administration

PRELIMINARY AGENDA

8:00-8:15	Welcome and Introductory Comments
<hr/>	
Session I: Disease Burden and Manifestations <i>Chair: Phyllis Leppert, M.D., NICHD</i>	
8:15-9:00	Keynote: Clinical Manifestations and Outcome of Uterine Leiomyoma Lee A. Learman, M.D., Ph.D., University of California, San Francisco
9:00-9:30	Molecular Characterization of Uterine Leiomyoma J. Carl Barrett, Ph.D., National Cancer Institute
9:30-10:00	Panel and General Discussion With the Patients' Perspective
10:00-10:30	<i>Break and Poster Set-up</i>
<hr/>	
Session II: Epidemiology and Genetics <i>Chair: Kenneth Olden, Ph.D., Sc.D., L.H.D., NIEHS</i>	
10:30-11:00	The NIEHS Uterine Fibroid Study Donna Day Baird, Ph.D., NIEHS
11:00-11:30	Genetic Links Cynthia Morton, Ph.D., Harvard Medical School, Brigham and Women's Hospital
11:30-12:00	Hereditary Fibroids Marston Linnehan, M.D., National Cancer Institute
12:00-12:30	Panel and General Discussion
12:30-1:30	<i>Lunch</i>
<hr/>	
Session III. Pathobiology of Fibroids <i>Chair: Darlene Dixon, DVM, Ph.D., NIEHS</i>	
1:30-2:00	The Fibroid Growth Study Barbara J. Davis, V.M.D, Ph.D., NIEHS
2:00-2:30	Signaling Pathways of Uterine Smooth Muscle Romana Nowak, Ph.D., University of Illinois
2:30-3:00	Molecular Mechanisms of Leiomyoma Growth Cheryl Walker, Ph.D., University of Texas M.D. Anderson Cancer Center
3:00-3:30	Panel and General Discussion
3:30-5:00	Session IV: Poster Presentations <i>Chair: Karen Haneke, Integrated Laboratory Systems</i>

8:00-8:15	Introductory Comments
<hr/>	
Session V: Advances in Clinical Management and Translational Frontiers <i>Chair: Estella Parrott, M.D., M.P.H., NICHD</i>	
8:15-8:45	What Do We Really Know About Management of Fibroids? Evan Myers, M.D., Duke University
8:45-9:15	Alternatives to Hysterectomy Valerie Montgomery Rice, M.D. Meharry Medical College
9:15-10:15	MRI Guided Focused Ultrasound Surgery for Uterine Fibroids Elizabeth A. Stewart, M.D., Harvard Medical School, Brigham and Women's Hospital
10:15-10:45	Panel and General Discussion
10:15-10:30	<i>Break</i>

<hr/>	
Session VI. Clinical Trials and Tribulations <i>Chair: Colin Pollard, FDA</i>	
10:30-10:40	Opening Remarks
10:40-10:55	Use of Antiprogestins for Treatment of Uterine Fibroids, Clinical Trials Kevin Fiscella, M.D., University of Rochester
10:55-11:10	Effectiveness of Azoprisnil in Treating Fibroids Kristof Chwalisz, M.D., Ph.D., TAP Pharmaceutical Products, Inc.
11:10-11:20	A Uterine Fibroid Symptom QoL Scoring Instrument James Spies, M.D., Georgetown University
11:20-11:35	Clinical Trial Design & Small Studies: a Coordinating Center Perspective Kay Dickersin, Ph.D., Brown University
11:35-11:50	Uterine Fibroids – Clinical Trial Design & Small Studies: A Clinical Perspective Keith B. Isaacson, M.D., Newton Wellesley Hospital
11:50-12:30	Panel Discussion
12:30-1:30	<i>Lunch</i>

<hr/>	
Session VII. New Therapeutic Targets <i>Chair: Cheryl Walker, Ph.D., University of Texas M.D. Anderson Cancer Center</i>	
1:30-2:00	TGFb Collagen-Keloid and Abnormal Mature Collagen Hypothesis James Segars, M.D., NICHD
2:00-2:30	Immune Response, Adenovirus Treatment and SERMS Serdar Bulun, M.D., Northwestern University Feinberg School of Medicine
2:30-3:00	Panel and General Discussion
3:00-3:15	<i>Break</i>

<hr/>	
Session VIII. Hot Topics <i>Chair: Susan Meikle, M.D., M.S.P.H., AHRQ</i>	
3:15-4:15	Selected Abstracts and Discussion

<hr/>	
Session IX. Charting the Course <i>Chair: Barbara Davis, V.M.D., Ph.D., NIEHS</i>	
4:15-5:15	Panel Discussion-Drs. Estella Parrott, Phyllis Leppert, J. Carl Barrett, Susan Meikle; Ms. Carla Dionne; and Audience Discussants
5:15-5:30	Closing Remarks

Register on-line at:
<http://www4.od.nih.gov/orwh/uterinefibroidmtg.html>

If mailing registration, send to:

Integrated Laboratory Systems, Inc.
Attn: Heather Vahdat
P.O. Box 13501
Research Triangle Park, NC 277709

I. Personal Information

Name: _____

Professional Degree(s): _____

Company Name: _____

Department: _____

Street Address: _____

City: _____ **State:** _____

Country: _____

Postal (Zip) Code: _____

Phone Number: _____

Fax Number: _____

Email Address: _____

II. Submission Information

I Plan to participate in the poster session.
ABSTRACT DUE: October 15, 2004

I am interested in my poster topic being considered for a "Hot Topic" Submission.

Information and requirements for submission of abstracts can be found at: <http://orwh.od.nih.gov/CallforAbstracts.pdf>

III. Registrant Information - Check all that apply

A. Type of Organization

- Academia Government Private Industry
 Military Other _____

B. Field of Work

- Mutagenicity Biotechnology Pathology
 Epidemiology Pharmacology Radiology
 Genetic Toxicology General Toxicology
 Reprod. & Dev. Toxicology Mechanisms
 Medicine Molecular Biology
 Other _____